e cc。 CA therapy on lung cancer or pancreatic cancer,specifically in combinaton ith other nnhe comnioof CTLA-blockadewh PD-1or PD-LI inhibrors is esd on different types of cancer However,patients treated with check-point blockade(specifically CTLA-4 blocking antibodies),or a combnation of check-point blocking antibodies,are at high risk of sufferngfom mreated adverse the el-tbodmmisre had the r cancer blood 9 At the same time the levels of circulating antibodies lower.suggestng that local administration of the i-A-therapyrversev PD-1inhibitors rresu G PDIanibody Nivolumab were publishedin1ppro er head and neck the firs g cance ed i v [81] Pembrolizumab isanother PD1 approved to treat melanoma and lung cance Antibody BGB-A317 isa PD-1 inhibitor(designed to not bind Fc gamma receptor D)in early clinical trials PD-L1 inhibitors In May 2016PD-L1 inhibitor was approved for treating bladder cancer 内d网o Other Polysaccharides Certain compounds found in mus immune system and Tcells and immune system cytokines and have been investigated in clinical trials as immunologic adjuvants. (often mistakenly called ago cus blazei)lentinula edodes (shiitake mush Grifola frondose Hericmrncure fungi that produce betagucans and have been testor Neoantigens